Dupilumab for hypereosinophilic syndrome with ongoing symptoms
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if dupilumab, added to your current treatment, can help with remaining symptoms of hypereosinophilic syndrome (HES) like asthma, eczema, nasal polyps, or eosinophilic esophagitis. You may qualify if you're already on a biologic therapy that lowers eosinophils but still have bothersome symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with hypereosinophilic syndrome (HES) with high eosinophil levels and organ damage in the past
- You are currently on a biologic like mepolizumab, reslizumab, or benralizumab for at least 24 weeks
- Your recent eosinophil count is low (below 500 cells per microliter)
- You still have at least one moderate symptom from asthma, eczema, nasal polyps, or eosinophilic esophagitis
- You must also be enrolled in another NIH study (94-I-0079) for eosinophil-related conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies depemokimab, a medicine meant to reduce flares in people with hypereosinophilic syndrome (HES). It also checks how safe the treatment is and how well it works over time.
This study follows people with long-term high eosinophils (a type of white blood cell) and related conditions to learn how the illness changes over time. It helps doctors understand patterns of organ involvement and outcomes, which may improve future care.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
This trial tests if dupilumab, a weekly injection, can improve the muscle function of the esophagus in people with eosinophilic esophagitis (EoE) who haven't gotten better with acid-reducing medications. Researchers want to see if it helps with swallowing and reduces inflammation.
Hear when a new Hypereosinophilic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.